DNA induced folding/fibrillation of alpha-synuclein: New insights in Parkinson's disease

Frontiers in Bioscience

Volumn 15, Issue 2, 2010, Pages 418-436

  Hegde, Muralidhar L ^a   Vasudevaraju, Padmaraju ^a   Jagannatha Rao, Kosagisharaf ^a  

^a CENTRAL FOOD TECHNOLOGICAL RESEARCH INSTITUTE   (India)

Author keywords

Alpha Synuclein; Alpha Synuclein conformation; Alpha Synuclein DNA interaction; Neurodegeneration; Parkinson's disease; Review

Indexed keywords

ALPHA SYNUCLEIN; DNA;

ANIMAL; BIOLOGICAL MODEL; CELL NUCLEUS; CHEMISTRY; CONFORMATION; GENETICS; HUMAN; METABOLISM; PARKINSON DISEASE; PATHOLOGY; PROTEIN BINDING; PROTEIN FOLDING; REVIEW;

ALPHA-SYNUCLEIN; ANIMALS; CELL NUCLEUS; DNA; HUMANS; MODELS, BIOLOGICAL; NUCLEIC ACID CONFORMATION; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN FOLDING;

EID: 77951248437     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3628     Document Type: Article

References (198)

1. Goedert M: Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2, 492-501 (2001) (Pubitemid 33676584)
2. Goedert M: Parkinson's disease and other alphasynucleinopathies. Clin Chem Lab Med 39, 308-312 (2001)
3. Spillantini MG, ML. Schmidt, VM Lee, JQ Trojanowski, R Jakes, M. Goedert: Alpha-synuclein in Lewy bodies. Nature 388, 839-840 (1997)
4. Baba M, S Nakajo, PH Tu, T Tomita, K Nakaya, VM Lee, JQ Trojanowski, T Iwatsubo: Aggregation of alphasynuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152, 879-884 (1998) (Pubitemid 28173348)
5. Wakabayashi K, M Yoshimoto, S Tsuji, H Takahashi: Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249, 180-182 (1998) (Pubitemid 28331545)
6. Ono K, M Hirohata, M Yamada: Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders. Curr Pharm Des 14, 3247-3266 (2008)
7. Troster AI: Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers. Neuropsychol Rev 18, 103-119 (2008)
8. Maroteaux L, JT Campanelli, RH Scheller: Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8, 2804-2815 (1988)
9. Gomez-Tortosa E, K Newell, MC Irizarry, JL Sanders, BT Hyman: alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol, 99, 352-357 (2000) (Pubitemid 30179572)
10. McLean PJ, S Ribich, BT Hyman: Subcellular localization of alpha-synuclein in primary neuronal cultures: effect of missense mutations. J Neural Transm Suppl 53-63 (2000)
11. Tanji K, F Mori, T Imaizumi, H Yoshida, T Matsumiya, W Tamo, M Yoshimoto, H Odagiri, M Sasaki, H Takahashi, K Satoh, K Wakabayashi: Upregulation of alpha-synuclein by lipopolysaccharide and interleukin-1 in human macrophages. Pathol Int 52, 572-577 (2002) (Pubitemid 35335039)
12. Leng Y, TN Chase, MC Bennett: Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm. J Biol Chem 276, 28212-28218 (2001) (Pubitemid 37391526)
13. Sangchot P, S Sharma, B Chetsawang, J Porter, P Govitrapong, M Ebadi: Deferoxamine attenuates ironinduced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev Neurosci 24, 143-153 (2002) (Pubitemid 36151444)
14. Goers J, AB Manning-Bog, AL McCormack, IS Millett, S Doniach, DA Di Monte, VN Uversky, AL Fink: Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42, 8465-8471 (2003) (Pubitemid 36875412)
15. Lin WL, MW DeLucia, DW Dickson: Alpha-synuclein immunoreactivity in neuronal nuclear inclusions and neurites in multiple system atrophy. Neurosci Lett 354, 99-102 (2004) (Pubitemid 38032843)
16. Zhang L, C Zhang, Y Zhu, Q Cai, P Chan, K Ueda, S Yu, H Yang: Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Res 1244, 40-52 (2008)
17. Hegde ML, KS Jagannatha Rao: Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease. Arch Biochem Biophys 418, 169-178 (2003) (Pubitemid 37159383)
18. Hegde ML, KSJ Rao: New evidence for DNA nuclease activity of alpha-synuclein: a molecular mechanism in understanding Parkinson's disease. J Neurochem 98, 114-115 (2006)
19. Hegde ML, KS Rao: DNA induces folding in alphasynuclein: understanding the mechanism using chaperone property of osmolytes. Arch Biochem Biophys 464, 57-69 (2007) (Pubitemid 47088357)
20. Cherny, D., W. Hoyer, V. Subramaniam & T. M. Jovin: Double-stranded DNA stimulates the fibrillation of alphasynuclein in vitro and is associated with the mature fibrils: an electron microscopy study. J Mol Biol, 344, 929-938 (2004) (Pubitemid 39491240)
21. Parkinson J: An essay on the Shaking Palsy (Sherwood, Neely and Jones) London (1817)
22. Rajput AH, S Birdi: Epidemiology of Parkinson's disease. Parkinsonism Relat Disord 3, 175-186 (1997) (Pubitemid 28188827)
23. Chung KK, VL Dawson, TM Dawson: New insights into Parkinson's disease. J Neurol 250 Suppl 3, 15-24 (2003) (Pubitemid 37297082)
24. Zhou C, Y Huang, S Przedborski: Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 1147, 93-104 (2008)
25. Lewy F, Lewandowski N, Abelsdorff G: In handbuch der neurologie. Springer Verlag Berlin 3, 920-923 (1912)
26. Olanow CW: An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 32 Suppl, S2-9 (1992)
27. Berg D, MB Youdim, P Riederer: Redox imbalance. Cell Tissue Res 318, 201-213 (2004) (Pubitemid 39362641)
28. Migliore L, R Scarpato, F Coppede, L Petrozzi, U Bonuccelli, V Rodilla: Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients. Int J Hyg Environ Health, 204, 61-66 (2001) (Pubitemid 33031902)
29. Jellinger KA: Cell death mechanisms in Parkinson's disease. J Neural Transm 107, 1-29 (2000) (Pubitemid 30077039)
30. Hirsch EC, S Hunot, B Faucheux, Y Agid, Y Mizuno, H Mochizuki, WG Tatton, N Tatton, WC Olanow: Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord 14, 383-385 (1999)
31. Cohen G: Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv Neurol 45, 119-125 (1987)
32. Youdim MB: Brain monoamine oxidase (MAO) B: a unique neurotoxin and neurotransmitter producing enzyme. Prog Neuropsychopharmacol Biol Psychiatry 13, 363-371 (1989) (Pubitemid 19163788)
33. Dexter DT, P Jenner, AH Schapira, CD Marsden: Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32 Suppl, S94-100 (1992)
34. Olanow CW: The pathogenesis of cell death in Parkinson's disease - 2007. Mov Disord 22, S335-S342 (2007) (Pubitemid 350134186)
35. Esposito E, V Di Matteo, G Di Giovanni: Death in the substantia nigra: a motor tragedy. Expert Rev Neurother 7, 677-697 (2007) (Pubitemid 46911617)
36. Lotharius J, P Brundin: Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11, 2395-2407 (2002) (Pubitemid 35174703)
37. Graham DG: Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14, 633-643 (1978) (Pubitemid 8402469)
38. Jenner P: Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13 Suppl 1, 24-34 (1998)
39. Sofic E, P Riederer, H Heinsen, H Beckmann, GP Reynolds, G Hebenstreit, MB Youdim: Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74, 199-205 (1988)
40. Saggu H, J Cooksey, D Dexter, FR Wells, A Lees, P Jenner, CD Marsden: A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53, 692-697 (1989) (Pubitemid 19207359)
41. Dexter DT, FR, Wells, AJ Lees, F Agid, Y Agid, P Jenner, CD Marsden: Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52, 1830-1836 (1989) (Pubitemid 19140770)
42. Alam ZI, A Jenner, SE Daniel, AJ Lees, N Cairns, CD Marsden, P Jenner, B Halliwell: Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8- hydroxyguanine levels in substantia nigra. J Neurochem 69, 1196-1203 (1997) (Pubitemid 27364841)
43. Burke RE: Programmed cell death and new discoveries in the genetics of parkinsonism. J Neurochem 104, 875-890 (2008) (Pubitemid 351143657)
44. Mecocci P, U MacGarvey, AE Kaufman, D Koontz, JM Shoffner, DC Wallace, MF Beal: Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 34, 609-616 (1993) (Pubitemid 23289414)
45. Ben-Shachar D, P Riederer, MB Youdim: Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem 57, 1609-1614 (1991) (Pubitemid 21922796)
46. Riederer P, E Sofic, WD Rausch, B Schmidt, GP Reynolds, K Jellinger, MB Youdim: Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52, 515-520 (1989) (Pubitemid 19037617)
47. Jellinger K, E Kienzl, G Rumpelmair, P Riederer, H Stachelberger, D Ben-Shachar, MB Youdim: Iron-melanin complex in substantia nigra of parkinsonian brains: an xray microanalysis. J Neurochem 59, 1168-1171 (1992)
48. Camins A, M Pallas, JS Silvestre: Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches. Methods Find Exp Clin Pharmacol 30, 43-65 (2008) (Pubitemid 351397455)
49. Gupta A, VL Dawson, TM Dawson: What causes cell death in Parkinson's disease? Ann Neurol 64 Suppl 2, S3-15 (2008)
50. Burke RE, NG Kholodilov: Programmed cell death: does it play a role in Parkinson's disease? Ann Neurol 44, S126-133 (1998) (Pubitemid 28423839)
51. Kingsbury AE, C. D. Mardsen & O. J. Foster: DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov Disord 13, 877-884 (1998) (Pubitemid 28517663)
52. Ziv I, A Barzilai, D Offen, N Nardi, E Melamed: Nigrostriatal neuronal death in Parkinson's disease-a passive or an active genetically-controlled process? J Neural Transm Suppl 49, 69-76 (1997) (Pubitemid 27351474)
53. Tatton NA, A Maclean-Fraser, WG Tatton, DP Perl, CW Olanow: A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 44, S142-148 (1998) (Pubitemid 28423841)
54. Ziv I, E Melamed: Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity? Mov Disord 13, 865-70 (1998) (Pubitemid 28517661)
55. Jenner P, CW Olanow: Understanding cell death in Parkinson's disease. Ann Neurol 44, S72-84 (1998) (Pubitemid 28423832)
56. Robbins JH: Parkinson's disease, twins, and the DNAdamage hypothesis. Ann Neurol 21, 412 (1987)
57. Gavrieli Y, Y Sherman, SA Ben-Sasson: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119, 493-501 (1992)
58. Gold R, M Schmied, G Giegerich, H Breitschopf, HP Hartung, KV Toyka, H Lassmann: Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest, 71, 219-225 (1994) (Pubitemid 24278174)
59. Anglade P, S Vyas, F Javoy-Agid, MT Herrero, PP Michel, J Marquez, A Mouatt-Prigent, M Ruberg, EC Hirsch, Y. Agid: Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12, 25-31 (1997) (Pubitemid 27106916)
60. Anglade P, S Vyas, EC Hirsch, Y Agid: Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 12, 603-10 (1997) (Pubitemid 27314689)
61. Tompkins MM, EJ Basgall, E Zamrini, WD Hill: Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol, 150, 119-131 (1997) (Pubitemid 27027103)
62. Olanow CW, P Jenner, D Brooks: Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 44, S167-174 (1998) (Pubitemid 28423845)
63. Tatton NA, HJ Rideout: Confocal microscopy as a tool to examine DNA fragmentation, chromatin condensation and other apoptotic changes in Parkinson's disease. Parkinsonism Relat Disord 5, 179-186 (1999) (Pubitemid 29408673)
64. Hegde ML, VB Gupta, M Anitha, T Harikrishna, SK Shankar, U Muthane, K Subba Rao, KS Jagannatha Rao: Studies on genomic DNA topology and stability in brain regions of Parkinson's disease. Arch Biochem Biophys 449, 143-156 (2006)
65. Suram A, KS Rao, KS Latha, MA. Viswamitra: First evidence to show the topological change of DNA from BDNA to Z-DNA conformation in the hippocampus of Alzheimer's brain. Neuromolecular Med 2, 289-297 (2002) (Pubitemid 37070588)
66. Kikuchi A, A Takeda, H Onodera, T Kimpara, K Hisanaga, N Sato, A Nunomura, RJ Castellani, G Perry, MA Smith, Y Itoyama: Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 9, 244-8 (2002) (Pubitemid 34261218)
67. Nunomura A, S Chiba, K Kosaka, A Takeda, RJ Castellani, MA Smith, G Perry: Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies. Neuroreport 13, 2035-2039 (2002) (Pubitemid 36005920)
68. Ikebe S, M Tanaka, K Ohno, W Sato, K Hattori, T Kondo, Y Mizuno, T Ozawa: Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 170, 1044-1048 (1990) (Pubitemid 20273372)
69. Ozawa T, M Tanaka, S Ikebe, K Ohno, T Kondo, Y Mizuno: Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. Biochem Biophys Res Commun 172, 483-489 (1990) (Pubitemid 20384446)
70. Zhang J, TJ Montine, MA Smith, SL Siedlak, G Gu, D Robertson, G Perry: The mitochondrial common deletion in Parkinson's disease and related movement disorders. Parkinsonism Relat Disord 8, 165-170 (2002) (Pubitemid 33089329)
71. Hofer A, T Gasser: New aspects of genetic contributions to Parkinson's disease. J Mol Neurosci 24, 417-424 (2004)
72. Calne DB, UK Rinne: Controversies in the management of Parkinson's disease. Mov Disord 1, 159-162 (1986)
73. Corti O, C Hampe, F Darios, P Ibanez, M Ruberg, A Brice: Parkinson's disease: from causes to mechanisms. C R Biol, 328, 131-142 (2005) (Pubitemid 40247058)
74. Farina E, SF Cappa, M Polimeni, E Magni, M Canesi, A Zecchinelli, G Scarlato, C Mariani: Frontal dysfunction in early Parkinson's disease. Acta Neurol Scand, 90, 34-38 (1994) (Pubitemid 24227254)
75. Calne S, B Schoenberg, W Martin, RJ Uitti, P Spencer, DB Calne: Familial Parkinson's disease: possible role of environmental factors. Can J Neurol Sci 14, 303-305 (1987) (Pubitemid 17147210)
76. Tanner CM, B Chen, W Wang, M Peng, Z Liu, X Liang, LC Kao, DW Gilley, CG Goetz, BS Schoenberg: Environmental factors and Parkinson's disease: a casecontrol study in China. Neurology 39, 660-664 (1989) (Pubitemid 19126962)
77. Good PF, CW Olanow, DP Perl: Neuromelanincontaining neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 593, 343-346 (1992)
78. Yasui M, T Kihira, K Ota: Calcium, magnesium and aluminum concentrations in Parkinson's disease. Neurotoxicology 13, 593-600 (1992)
79. Hertzman C, M Wiens, B Snow, S Kelly, D Calne: A case-control study of Parkinson's disease in a horticultural region of British Columbia. Mov Disord 9, 69-75 (1994) (Pubitemid 24022617)
80. Gorell JM, CC Johnson, BA Rybicki, EL Peterson, GX Kortsha, GG Brown, RJ Richardson: Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20, 239-247 (1999)
81. Altschuler E: Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. Med Hypotheses 53, 22-23 (1999) (Pubitemid 29391318)
82. Le Couteur DG, AJ McLean, MC Taylor, BL Woodham, PG Board: Pesticides and Parkinson's disease. Biomed Pharmacother 53, 122-130 (1999) (Pubitemid 29507874)
83. Hegde ML, P Shanmugavelu, B Vengamma, TS Rao, RB Menon, RV Rao, KS Rao: Serum trace element levels and the complexity of inter-element relations in patients with Parkinson's disease. J Trace Elem Med Biol 18, 163-171 (2004) (Pubitemid 40007762)
84. Pande MB, P Nagabhushan, ML Hegde, TS Rao, KS Rao: An algorithmic approach to understand trace elemental homeostasis in serum samples of Parkinson disease. Comput Biol Med 35, 475-493 (2005) (Pubitemid 40409692)
85. Gupta VB, S Anitha, ML Hegde, L Zecca, RM Garruto, R Ravid, SK Shankar, R Stein, P Shanmugavelu, KS Jagannatha Rao: Aluminium in Alzheimer's disease: are we still at a crossroad? Cell Mol Life Sci 62, 143-158 (2005) (Pubitemid 40193039)
86. Hegde ML, Bharathi, S Anitha, C Venugopal, R Jagannathan, P Poddar, P Srinivas, K Sambamurti KSJ Rao, J Scancar, L Messori, L Zecca, P Zatta. Challenges Associated With Metal Chelation Therapy in Alzheimer's Disease. J. Alzheimer Dis In Press, (2009)
87. Shanmugavelu P, TSS Rao, ML Hegde, MS Mustak, RB Menon, RV Rao, KSJ Rao. Altered trace elemental homeostasis in neurodegenerative (Alzheimer's and Parkinson's) and neuropsychiatric (bipolar) disorder' In. Neurodegenerative diseases: Alzheimer's disease (Abs). J Neurochem 88, 49 (2004)
88. Fernandez M, L Villalonga Mde, A Fragoso, R Cao, R Villalonga: Stabilization of alpha-chymotrypsin by modification with beta-cyclodextrin derivatives. Biotechnol Appl Biochem 36, 235-9 (2002) (Pubitemid 36009073)
89. George JM: The synucleins. Genome Biol 3, REVIEWS 3002.1-3002.6 (2002)
90. Conway KA, JD Harper, PT Lansbury, Jr.: Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563 (2000) (Pubitemid 30148907)
91. El-Agnaf OM, R Jakes, MD Curran, A Wallace: Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett 440, 67-70 (1998) (Pubitemid 28558737)
92. Polymeropoulos MH, C Lavedan, E Leroy, SE Ide, A Dehejia, A Dutra, B Pike, H Root, J Rubenstein, R Boyer, ES Stenroos, S Chandrasekharappa, A Athanassiadou, T Papapetropoulos, WG Johnson, AM Lazzarini, RC Duvoisin, G Di Iorio, L I Golbe, RL Nussbaum: Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047 (1997) (Pubitemid 27443610)
93. Kruger R, W Kuhn, T Muller, D Woitalla, M Graeber, S Kosel, H Przuntek, JT Epplen, L Schols, O Riess: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18, 106-108 (1998)
94. Zarranz JJ, J Alegre, JC Gomez-Esteban, E Lezcano, R Ros, I Ampuero, L Vidal, J Hoenicka, O Rodriguez, B Atares, V Llorens, E Gomez Tortosa, T del Ser, DG Munoz, JG de Yebenes: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55, 164-173 (2004) (Pubitemid 38166992)
95. Vogel G: Gene discovery offers tentative clues to Parkinson's. Science 276, 1973 (1997) (Pubitemid 27443575)
96. Heintz NH: Phosphorylation of proteins that regulate the cell cycle and cancer: an international perspective. Jpn J Clin Oncol 27, 288 (1997)
97. Trojanowski JQ, VM Lee: Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain. Parkinsonism Relat Disord 7, 247-251 (2001) (Pubitemid 32372507)
98. Lippa CF, H Fujiwara, DM Mann, B Giasson, M Baba, ML Schmidt, LE Nee, B O'Connell, DA Pollen, P St George-Hyslop, B Ghetti, D Nochlin, TD Bird, NJ Cairns, VM Lee, T Iwatsubo, JQ Trojanowski: Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153, 1365-70 (1998) (Pubitemid 28509891)
99. Irizarry MC, W Growdon, T Gomez-Isla, K Newell, JM George, DF Clayton, BT Hyman: Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 57, 334-337 (1998) (Pubitemid 28182631)
100. Lippa CF, ML Schmidt, VM Lee, JQ Trojanowski: Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 45, 353-357 (1999) (Pubitemid 29120040)
101. Mezey E, A Dehejia, G Harta, MI Papp, MH Polymeropoulos, MJ Brownstein: Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Nat Med 4, 755-757 (1998) (Pubitemid 28331004)
102. Spillantini MG, RA Crowther, R Jakes, M Hasegawa, M Goedert: alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95, 6469-6473 (1998) (Pubitemid 28249037)
103. Takeda A, M Hashimoto, M Mallory, M Sundsumo, L Hansen, A Sisk, E Masliah: Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest 78, 1169-1177 (1998) (Pubitemid 28440832)
104. Wakabayashi K, K Matsumoto K Takayama, M Yoshimoto, H Takahashi: NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett 239, 45-48 (1997) (Pubitemid 28055846)
105. Clayton DF, JM George: The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21, 249-254 (1998) (Pubitemid 28239982)
106. George JM, H Jin, WS Woods, DF Clayton: Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361-372 (1995)
107. Segrest JP, MK Jones, H De Loof, CG Brouillette, YV Venkatachalapathi, GM Anantharamaiah: The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 33, 141-166 (1992)
108. Segrest JP, H De Loof, JG Dohlman, CG Brouillette, GM Anantharamaiah: Amphipathic helix motif: classes and properties. Proteins 8, 103-117 (1990) (Pubitemid 20262536)
109. Perrin RJ, WS Woods, DF Clayton, JM George: Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using sitedirected mutagenesis. J Biol Chem 275, 34393-34398 (2000)
110. Davidson WS, A Jonas, DF Clayton, JM George: Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem, 273, 9443-9449 (1998) (Pubitemid 28183026)
111. Bussell R Jr, D Eliezer: A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J Mol Biol 329, 763-778 (2003) (Pubitemid 36629369)
112. Chandra S, X Chen, J Rizo, R Jahn, TC Sudhof: A broken alpha -helix in folded alpha -Synuclein. J Biol Chem 278, 15313-15318 (2003) (Pubitemid 36799869)
113. Eliezer D, E Kutluay, R Bussell Jr, G Browne: Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307, 1061-1073 (2001) (Pubitemid 33029953)
114. Li X, P Romero, M Rani, AK Dunker, Z Obradovic: Predicting Protein Disorder for N-, C-, and Internal Regions. Genome Inform Ser Workshop Genome Inform 10, 30-40 (1999)
115. Perrin RJ, WS Woods, DF Clayton, JM George: Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem 276, 41958-41962 (2001)
116. Cole NB, DD Murphy, T Grider, S Rueter, D Brasaemle, RL Nussbaum: Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem 277, 6344-6352 (2002) (Pubitemid 34968427)
117. Jo E, J McLaurin, CM Yip, P St George-Hyslop, PE Fraser: alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem 275, 34328-34334 (2000)
118. Lee MK, W Stirling, Y Xu, X Xu, D Qui, AS Mandir, TM Dawson, NG Copeland, NA Jenkins, DL Price: Human alpha-synuclein-harboring familial Parkinson's diseaselinked Ala-53 -> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 99, 8968-8973 (2002) (Pubitemid 34693667)
119. Munishkina, LA, C Phelan, VN Uversky, AL Fink: Conformational behavior and aggregation of alphasynuclein in organic solvents: modeling the effects of membranes. Biochemistry 42, 2720-2730 (2003) (Pubitemid 36330626)
120. Feany MB, WW Bender: A Drosophila model of Parkinson's disease. Nature 404, 394-398 (2000) (Pubitemid 30164341)
121. Masliah E, E Rockenstein: Genetically altered transgenic models of Alzheimer's disease. J Neural Transm Suppl 59, 175-183 (2000) (Pubitemid 30479418)
122. Hegde ML, S Anitha, KSJ Rao: Are monomeroligomer- aggregates of amyloidogenic peptides toxic species in neurodegeneration? A new experimental evidence (Abs). Neurobiol Aging 25, 170 (2004)
123. Yamada M, T Iwatsubo, Y Mizuno, H.Mochizuki: Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 91, 451-461 (2004) (Pubitemid 39363444)
124. Chesselet MF: In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp Neurol 209, 22-27 (2008)
125. Lucking CB, A Brice: Alpha-synuclein and Parkinson's disease. Cell Mol Life Sci 57, 1894-1908 (2000) (Pubitemid 32102585)
126. Ostrerova N, L Petrucelli, M Farrer, N Mehta, P Choi, J Hardy, B Wolozin: alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 19, 5782-5791 (1999) (Pubitemid 29327915)
127. Hsu LJ, M Mallory, Y Xia, I Veinbergs, M Hashimoto, M Yoshimoto, LJ Thal, T Saitoh, E Masliah: Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alphasynuclein) during murine brain development. J Neurochem 71, 338-344 (1998) (Pubitemid 28292567)
128. Bayer TA, P Jakala, T Hartmann, R Egensperger, R Buslei, P Falkai, K Beyreuther: Neural expression profile of alpha-synuclein in developing human cortex. Neuroreport 10, 2799-2803 (1999) (Pubitemid 30004108)
129. Stefanis L, N Kholodilov, HJ Rideout, RE Burke, LA Greene: Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. J Neurochem 76, 1165-1176 (2001) (Pubitemid 32167390)
130. Jenco JM, A Rawlingson, B Daniels, AJ Morris: Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37, 4901-4909 (1998) (Pubitemid 28175972)
131. Klein J, R Lindmar, K Loffelholz: Muscarinic activation of phosphatidylcholine hydrolysis. Prog Brain Res 109, 201-208 (1996) (Pubitemid 27047089)
132. Murphy DD, SM Rueter, JQ Trojanowski, VM Lee: Synucleins are developmentally expressed, and alphasynuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20, 3214-3220 (2000) (Pubitemid 30263139)
133. Cole NB, DD Murphy: The cell biology of alphasynuclein: a sticky problem? Neuromolecular Med 1, 95-109 (2002) (Pubitemid 37012519)
134. Dev, K. K., K. Hofele, S. Barbieri, V. L. Buchman & H. van der Putten: Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology, 45, 14-44 (2003) (Pubitemid 36695009)
135. Kalra S, C Bergeron, AE Lang: Lewy body disease and dementia. A review. Arch Intern Med 156, 487-493 (1996) (Pubitemid 26081734)
136. Gomez-Tortosa E, AO Ingraham, MC Irizarry, BT Hyman: Dementia with Lewy bodies. J Am Geriatr Soc 46, 1449-1458 (1998) (Pubitemid 28511889)
137. Tsuboi Y, H Uchikado, DW Dickson: Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disor 13 Suppl 3, S221-224 (2007) (Pubitemid 351215244)
138. Pletnikova O, N West, MK Lee, GL Rudow, RL Skolasky, TM Dawson, L Marsh, JC Troncoso: Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 26, 1183-1192 (2005) (Pubitemid 40726011)
139. Lavedan C: The synuclein family. Genome Res 8, 871-880 (1998) (Pubitemid 28495441)
140. Galvin JE, TM Schuck, VM Lee, JQ Trojanowski: Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra. Exp Neurol 168, 347-355 (2001) (Pubitemid 32289770)
141. Petersen K, OF Olesen, JD Mikkelsen: Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex. Neuroscience 91, 651-659 (1999) (Pubitemid 29193274)
142. Vila M, S Vukosavic, V Jackson-Lewis, M Neystat, M Jakowec, S Przedborski: Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 74, 721-729 (2000) (Pubitemid 30053745)
143. Hashimoto M, M Yoshimoto, A Sisk, LJ Hsu, M Sundsmo, A Kittel, T Saitoh, A Miller, E Masliah: NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. Biochem Biophys Res Commun 237, 611-616 (1997) (Pubitemid 27434734)
144. Schneider BL, CR Seehus, EE Capowski, P Aebischer, SC Zhang, CN Svendsen: Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. Hum Mol Genet 16, 651-666 (2007) (Pubitemid 46591118)
145. Mori F, K Tanji, M Yoshimoto, H Takahashi, K Wakabayashi: Immunohistochemical comparison of alphaand beta-synuclein in adult rat central nervous system. Brain Res 941, 118-126 (2002) (Pubitemid 34603290)
146. Specht CG, CM Tigaret, GF Rast, A Thalhammer, Y Rudhard, R Schoepfer: Subcellular localisation of recombinant alpha- and gamma-synuclein. Mol Cell Neurosci 28, 326-334 (2005) (Pubitemid 40202593)
147. Yu S, X Zuo, Y Li, C Zhang, M Zhou, YA Zhang, K Ueda, P Chan: Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci Lett 367, 34-39 (2004) (Pubitemid 39078779)
148. Yu S, X Li, G Liu, J Han, C Zhang, Y Li, S Xu, C Liu, Y Gao, H Yang, K Ueda, P Chan: Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience 145, 539-555 (2007) (Pubitemid 46350815)
149. Torrisi MR, LV Lotti, A Pavan, G Migliaccio, S Bonatti: Free diffusion to and from the inner nuclear membrane of newly synthesized plasma membrane glycoproteins. J Cell Biol 104, 733-737 (1987)
150. Baptista MJ, C O'Farrell, S Daya, R Ahmad, DW Miller, J Hardy, MJ Farrer, MR Cookson: Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem 85, 957-968 (2003) (Pubitemid 36578627)
151. Kontopoulos E, JD Parvin, MB Feany: Alphasynuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15, 3012-3023 (2006) (Pubitemid 44530705)
152. Migliore L, L Petrozzi, C Lucetti, G Gambaccini, S Bernardini, R Scarpato, F Trippi, R Barale, G Frenzilli, V Rodilla, U Bonuccelli: Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58, 1809-1815 (2002) (Pubitemid 34663582)
153. Tabner BJ, S Turnbull, OM El-Agnaf, D Allsop: Formation of hydrogen peroxide and hydroxyl radicals from A (beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 32, 1076-1083 (2002) (Pubitemid 34603345)
154. Martin FL, SJ Williamson, KE Paleologou, R Hewitt, OM El-Agnaf, D Allsop: Fe (II)-induced DNA damage in alpha-synuclein-transfected human dopaminergic BE (2)- M17 neuroblastoma cells: detection by the Comet assay. J Neurochem 87,
155. Hegde ML, S Anitha, KS Latha, MS Mustak, R Stein, R Ravid, KS Rao: First evidence for helical transitions in supercoiled DNA by amyloid Beta Peptide (1-42) and aluminum: a new insight in understanding Alzheimer's disease. J Mol Neurosci 22, 19-31 (2004) (Pubitemid 41359012)
156. Suram A, ML Hegde, KS Rao: A new evidence for DNA nicking property of amyloid beta-peptide (1-42): relevance to Alzheimer's disease. Arch Biochem Biophys 463, 245-252 (2007) (Pubitemid 47030340)
157. Uversky VN, J Li, AL Fink: Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276, 44284-44296 (2001)
158. Grabenauer M, SL Bernstein, JC Lee, T Wyttenbach, NF Dupuis, HB Gray, JR. Winkler, MT Bowers: Spermine binding to Parkinson's protein alpha-synuclein and its disease-related A30P and A53T mutants. J Phys Chem B 112, 11147-11154 (2008)
159. Uversky VN, J Li, AL Fink: Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276, 10737-10744 (2001) (Pubitemid 38089246)
160. Fink AL: Compact intermediate states in protein folding. Annu Rev Biophys Biomol Struct 24, 495-522 (1995)
161. Wetzel R: For protein misassembly, it's the "I" decade. Cell, 86, 699-702 (1996)
162. Uversky VN, J Li, AL Fink: Trimethylamine-N-oxideinduced folding of alpha-synuclein. FEBS Lett 509, 31-35 (2001)
163. Zecca L, A Stroppolo, A Gatti, D Tampellini, M Toscani, M Gallorini, G Giaveri, P Arosio, P Santambrogio, RG Fariello, E Karatekin, MH Kleinman, N Turro, O Hornykiewicz, FA Zucca: The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A 101, 9843-9848 (2004) (Pubitemid 38869324)
164. Zecca L, MB Youdim, P Riederer, JR Connor, RR Crichton: Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5, 863-873 (2004) (Pubitemid 39482155)
165. Gotz ME, K Double, M Gerlach, MB Youdim, P Riederer: The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 1012, 193-208 (2004) (Pubitemid 38455479)
166. Dexter DT, A Carayon, M Vidailhet, M Ruberg, F Agid, Y Agid, AJ Lees, FR Wells, P Jenner, CD Marsden: Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 55, 16-20 (1990)
167. Gabus C, S Auxilien, C Pechoux, D Dormont, W Swietnicki, M Morillas, W Surewicz, P Nandi, JL Darlix: The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein. J Mol Biol 307, 1011-1021 (2001) (Pubitemid 33031273)
168. Nandi PK: Polymerization of human prion peptide HuPrP 106-126 to amyloid in nucleic acid solution. Arch Virol 143, 1251-1263 (1998) (Pubitemid 28371590)
169. Ahn BW, DU Song, YD Jung, KO Chay, MA Chung, SY Yang, BA Shin: Detection of beta-amyloid peptide aggregation using DNA electrophoresis. Anal Biochem 284, 401-405 (2000)
170. Jang JH, YJ Surh: beta-Amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann N Y Acad Sci 973, 228-236 (2002)
171. Kampers T, P Friedhoff, J Biernat, EM Mandelkow, E Mandelkow: RNA stimulates aggregation of microtubuleassociated protein tau into Alzheimer-like paired helical filaments. FEBS Lett 399, 344-349 (1996) (Pubitemid 26426879)
172. Nandi PK, E Leclerc, JC Nicole, M Takahashi: DNAinduced partial unfolding of prion protein leads to its polymerisation to amyloid. J Mol Biol 322, 153-161 (2002) (Pubitemid 36132675)
173. Nandi PK, E Leclerc: Polymerization of murine recombinant prion protein in nucleic acid solution. Arch Virol 144, 1751-1763 (1999) (Pubitemid 29490035)
174. Cordeiro Y, F Machado, L Juliano, MA Juliano, RR Brentani, D Foguel, JL Silva: DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation. J Biol Chem 276, 49400-49409 (2001)
175. Gabus C, E Derrington, P Leblanc, J Chnaiderman, D Dormont, W Swietnicki, M Morillas, WK Surewicz, D Marc, P Nandi, JL Darlix: The prion protein has RNA binding and chaperoning properties characteristic of nucleocapsid protein NCP7 of HIV-1. J Biol Chem 276, 19301-19309 (2001)
176. Gupta VB, ML Hegde, KS Rao: Role of protein conformational dynamics and DNA integrity in relevance to neuronal cell death in neurodegeneration. Curr Alzheimer Res 3, 297-309 (2006) (Pubitemid 44351474)
177. Rao KS, ML Hegde, S Anitha, M Musicco, FA Zucca, NJ Turro, L Zecca: Amyloid beta and neuromelanin-toxic or protective molecules? The cellular context makes the difference. Prog Neurobiol 78, 364-373 (2006) (Pubitemid 43850101)
178. Weinreb PH, W Zhen, AW Poon, KA Conway, PT Lansbury Jr,.: NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715 (1996) (Pubitemid 26363912)
179. Uversky VN: Natively unfolded proteins: a point where biology waits for physics. Protein Sci 11, 739-756 (2002) (Pubitemid 34241284)
180. Uversky VN, JR Gillespie, AL Fink: Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins 41, 415-427 (2000)
181. Uversky VN: What does it mean to be natively unfolded? Eur J Biochem 269, 2-12 (2002) (Pubitemid 34107333)
182. Crowther RA, R Jakes, MG Spillantini, M.Goedert: Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett 436, 309-312 (1998) (Pubitemid 28482951)
183. Wood SJ, J Wypych, S Steavenson, JC Louis, M Citron, AL Biere: alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274, 19509-19512 (1999)
184. Giasson BI, K Uryu, JQ Trojanowski, VM Lee: Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274, 7619-7622 (1999)
185. Narhi L, SJ Wood, S Steavenson, Y Jiang, GM Wu, D Anafi, SA Kaufman, F Martin, K Sitney, P Denis, JC Louis, J Wypych, AL Biere, M Citron: Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 274, 9843-9846 (1999)
186. Serpell LC, J Berriman, R Jakes, M Goedert, RA Crowther: Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A 97, 4897-4902 (2000) (Pubitemid 30238654)
187. Li J, VN Uversky, AL Fink: Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 11604-11613 (2001) (Pubitemid 32911305)
188. Hoyer W, T Antony, D Cherny, G Heim, TM Jovin, V Subramaniam: Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol 322, 383-393 (2002)
189. Lee HG, X Zhu, A Takeda, G Perry, MA Smith: Emerging evidence for the neuroprotective role of alphasynuclein. Exp Neurol 200, 1-7 (2006) (Pubitemid 44080768)
190. Lee HG, RB Petersen, X Zhu, K Honda, G Aliev, MA Smith, G Perry: Will preventing protein aggregates live up to its promise as prophylaxis against neurodegenerative diseases? Brain Pathol 13, 630-8 (2003) (Pubitemid 37420705)
191. Hashimoto M, LJ Hsu, E Rockenstein, T Takenouchi, M Mallory, E Masliah: alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J Biol Chem 277, 11465-11472 (2002) (Pubitemid 34952915)
192. Masliah E, E Rockenstein, I Veinbergs, M Mallory, M Hashimoto, A Takeda, Y Sagara, A Sisk, L Mucke: Dopaminergic loss and inclusion body formation in alphasynuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (2000) (Pubitemid 30112148)
193. Matsuoka Y, M Vila, S Lincoln, A McCormack, M Picciano, J LaFrancois, X Yu, D Dickson, WJ Langston, E McGowan, M Farrer, J Hardy, K Duff, S Przedborski, DA Di Monte: Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 8, 535-539 (2001) (Pubitemid 32566143)
194. Ostrerova-Golts N, L Petrucelli, J Hardy, JM Lee, M Farer, B Wolozin: The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20, 6048-6054 (2000) (Pubitemid 30658398)
195. Manning-Bog, AB, AL McCormack, MG Purisai, LM Bolin, DA Di Monte: Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 23, 3095-3099 (2003) (Pubitemid 36531948)
196. Hasegawa T, M Matsuzaki, A Takeda, A Kikuchi, H Akita, G Perry, MA Smith & Y. Itoyama: Accelerated alpha-synuclein aggregation after differentiation of SHSY5Y neuroblastoma cells. Brain Res, 1013, 51-59 (2004) (Pubitemid 38757408)
197. Matsuzaki M, T Hasegawa, A Takeda, A Kikuchi, K Furukawa, Y Kato, Y Itoyama: Histochemical features of stress-induced aggregates in alpha-synuclein overexpressing cells. Brain Res 1004, 83-90 (2004) (Pubitemid 38368064)
198. Rathke-Hartlieb S, PJ Kahle, M Neumann, L Ozmen, S Haid, M Okochi, C Haass, JB Schulz: Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J Neurochem 77, 1181-1184 (2001) (Pubitemid 32467072)